Sign In / Join

close

Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients

November 15, 2024

New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.

Is it Safe for R/R DLBCL Patients to Receive CAR T-cell Therapy in an Outpatient Setting?

October 22, 2024

Is it safe for relapsed/refractory non-Hodgkin lymphoma patients, including DLBCL, to receive CAR T-cell therapy in an outpatient setting?

ViPOR Study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

October 15, 2024

Dr. Mark Roschewski shared with HealthTree about his presentation at ASH 2023 on the results of a regimen known as ViPOR, designed for patients with R/R DLBCL.

EHA 2024: Can Patients Over 75 Be Treated with CAR T-cell Therapy?

July 16, 2024

Dr. Pierre Bories shared research findings about similarities and differences between older and younger DLBCL patients treated with CAR T-cell therapy.

Epcoritamab (Epkinly) Now FDA-Approved for Relapsed/Refractory Follicular Lymphoma

July 15, 2024

The bispecific antibody epcoritamab (Epkinly) was recently FDA-approved for the treatment of relapsed/refractory follicular lymphoma. Find out more!

EHA 2024: Golcadomide Alone or Combined with Rituximab in Relapsed/Refractory Follicular Lymphoma

July 09, 2024

First results of golcadomide, a new CELMoD, in monotherapy and with rituximab relapsed/refractory follicular lymphoma (non-Hodgkin Lymphoma) by Dr. Chavez.

ASCO 2024: ECHELON-3 Study Updates of Brentuximab Vedotin, Lenalidomide & Rituximab Combo for R/R DLBCL

June 13, 2024

Dr. Jeong Kim shares findings about how the treatment combination of brentuximab vedotin, lenalidomide, and rituximab helps R/R DLBCL patients.

What is the ASCO Conference?

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

What is the ASCO Conference?

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

Evorpacept - A Next-Generation CD47 Inhibitor in Phase I Study for Patients With Relapsed-Refractory Lymphoma

May 06, 2024

Discover Evorpacept: A Next-Generation CD47 Checkpoint Inhibitor For Cancer Treatment with Enhanced Safety and Efficacy.

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Conferences

Recent Articles

Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma Patients

Is it Safe for R/R DLBCL Patients to Receive CAR T-cell Therapy in an Outpatient Setting?

ViPOR Study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

EHA 2024: Can Patients Over 75 Be Treated with CAR T-cell Therapy?

Epcoritamab (Epkinly) Now FDA-Approved for Relapsed/Refractory Follicular Lymphoma

EHA 2024: Golcadomide Alone or Combined with Rituximab in Relapsed/Refractory Follicular Lymphoma

ASCO 2024: ECHELON-3 Study Updates of Brentuximab Vedotin, Lenalidomide & Rituximab Combo for R/R DLBCL

What is the ASCO Conference?

What is the ASCO Conference?

Evorpacept - A Next-Generation CD47 Inhibitor in Phase I Study for Patients With Relapsed-Refractory Lymphoma

Get the latest thought leadership on your Non-Hodgkin Lymphoma delivered straight to your inbox

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info